脂质纳米颗粒:对生物利用度和药代动力学变化的影响
Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes.
作者信息
Souto Eliana B, Müller Rainer H
机构信息
Faculty of Health Sciences, Fernando Pessoa University, Rua Carlos da Maia, 296, P-4200-150, Porto, Portugal.
出版信息
Handb Exp Pharmacol. 2010(197):115-41. doi: 10.1007/978-3-642-00477-3_4.
The main aim of pharmaceutical technology research is the design of successful formulations for effective therapy, taking into account several issues including therapeutic requirements and patient compliance. In this regard, several achievements have been reported with colloidal carriers, in particular with lipid nanoparticles, due to their unique physicochemical properties. For several years these carriers have been showing potential success for several administration routes, namely oral, dermal, parenteral, and, more recently, for pulmonary and brain targeting. The present chapter provides a review of the use of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) to modify the release profile and the pharmacokinetic parameters of active pharmaceutical ingredients (APIs) incorporated in these lipid matrices, aiming to modify the API bioavailability, either upwards or downwards depending on the therapeutic requirement. Definitions of the morphological characteristics, surface properties, and polymorphic structures will also be given, emphasizing their influence on the incorporation parameters of the API, such as yield of production, loading capacity, and encapsulation efficiency.
药物技术研究的主要目标是设计出成功的制剂用于有效治疗,同时要考虑包括治疗需求和患者依从性等多个问题。在这方面,由于其独特的物理化学性质,胶体载体尤其是脂质纳米粒已有多项成果报道。多年来,这些载体在多种给药途径(即口服、皮肤、肠胃外给药,以及最近的肺部和脑部靶向给药)中都显示出潜在的成功。本章综述了固体脂质纳米粒(SLN)和纳米结构脂质载体(NLC)在修饰这些脂质基质中所含活性药物成分(API)的释放曲线和药代动力学参数方面的应用,目的是根据治疗需求上调或下调API的生物利用度。还将给出形态特征、表面性质和多晶型结构的定义,强调它们对API包合参数(如产率、载药量和包封率)的影响。